Company Profile
Edgewise Therapeutics Stock Price, News & Analysis
- Ticker:
- EWTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
44.99 USD (+0.64%)
Close
Last updated: August 5, 2026
4.01B USD
Market cap
Why the stock is moving
As of Aug 5, 2026, EWTX closed up 0.64% at $44.99. No new same-company headline was identified in the current news window.
Company overview
Business overview
Edgewise Therapeutics is a muscle-disease company focused on cardiac and muscular disorders. Its platform is built around precision therapies for diseases with clear biological targets.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Edgewise sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical data, dose strategy, and the potential to build a focused muscle-disease franchise.
Position Within the Biotechnology Landscape
Edgewise is a catalyst-sensitive muscle-disease biotech whose stock moves on clinical differentiation and safety.
Future catalysts
Edgewise Therapeutics's catalysts are sevasemten in Duchenne and its cardiomyopathy programs, which are the two things most likely to move the stock. The next update matters because the company still needs to prove the muscle-disease thesis.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Edgewise Therapeutics (EWTX)?
Edgewise Therapeutics (EWTX) most recently closed at 44.99 USD, a +0.64% move versus the previous session.
What is the market cap of Edgewise Therapeutics (EWTX)?
Edgewise Therapeutics currently has a market capitalization of 4.01B USD on BioPharmSignal.
What does Edgewise Therapeutics do?
Edgewise Therapeutics is a muscle-disease company focused on cardiac and muscular disorders. Its platform is built around precision therapies for diseases with clear biological targets.
On which exchange is EWTX stock listed?
Edgewise Therapeutics (EWTX) is associated with NASDAQ, United States, Biopharma.
What is Edgewise?
Edgewise Therapeutics's catalysts are sevasemten in Duchenne and its cardiomyopathy programs, which are the two things most likely to move the stock.
Which conditions is Edgewise Therapeutics targeting with Edgewise?
Edgewise Therapeutics's catalysts are sevasemten in Duchenne and its cardiomyopathy programs, which are the two things most likely to move the stock.
How does Edgewise Therapeutics describe recent progress with Edgewise?
Edgewise Therapeutics's catalysts are sevasemten in Duchenne and its cardiomyopathy programs, which are the two things most likely to move the stock.
What is Therapeutics?
Edgewise Therapeutics is a muscle-disease company focused on cardiac and muscular disorders.